This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Atrial Fibrillation Heart Failure Preserved Ejection Fraction 
Heart BMJ
MARCH 26, 2025
Background Heart failure with preserved ejection fraction is a recognised outcome in patients with myocardial infarction, although heart failure with reduced ejection fraction is more common. fold higher risk of heart failure with preserved ejection fraction (95% CI 1.30
52 
Journal of Cardiovascular Electrophysiology
MARCH 10, 2025
It highlights the confluence of two major cardiovascular epidemics, atrial fibrillation and heart failure, with preserved ejection fraction. In these conditions, advances in electrophysiology and heart failure physiology are intertwined and are integrated in this review.
JAMA Cardiology
MARCH 28, 2025
This secondary analysis of the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) randomized clinical trial examines the efficacy and safety of finerenone in patients with heart failure with mildly reduced or preserved ejection fraction according to the presence and type of atrial fibrillation. (..)
JAMA Cardiology
APRIL 23, 2024
This systematic review and meta-analysis investigates the efficacy of catheter ablation compared with rate or rhythm control among patients with atrial fibrillation and heart failure.
Heart BMJ
MARCH 26, 2025
Heart failure (HF) is one of the significant complications in patients with myocardial infarction (MI), leading to increased risk for cardiovascular morbidity and mortality. Common predictors include older age, prior hypertension, diabetes and atrial fibrillation. HFrEF is more commonly.
Frontiers in Cardiovascular Medicine
NOVEMBER 17, 2024
BackgroundAnemia is a common complication in patients with heart failure and is associated with left ventricular systolic dysfunction.
DAIC
JULY 31, 2024
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
111 
Frontiers in Cardiovascular Medicine
JANUARY 28, 2024
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) have emerged as major age-related epidemics within cardiology. Indeed, these two conditions are commonly found in the same individual, so much so that AF has been used in proposed diagnostic criteria for HFpEF.
HeartRhythm
OCTOBER 21, 2024
Clinical outcomes among patients with atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) treated with catheter ablation (CA) versus antiarrhythmic therapy (AAT) are not well-known.
HeartRhythm
APRIL 30, 2024
The efficacy of catheter ablation as a treatment approach for patients with concurrent atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) has been inadequately investigated.
HeartRhythm
JANUARY 6, 2025
Atrial fibrillation (AF) is a common arrhythmia in patients with heart failure (HF). Catheter ablation of AF has been proven to be an effective therapeutic option for AF management in HF, particularly in heart failure with reduced ejection fraction (HFrEF) [2, 3].
American College of Cardiology
FEBRUARY 23, 2024
What is the prevalence of subclinical atrial fibrillation (AF) in patients with heart failure and preserved ejection fraction (HFpEF), and how does it impact outcomes?
HeartRhythm
APRIL 14, 2024
The benefit of catheter ablation in patients with atrial fibrillation (AF) for patients with heart failure with preserved ejection fraction (HFpEF) remains uncertain.
DAIC
JUNE 4, 2024
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
HeartRhythm
SEPTEMBER 4, 2024
Heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are comorbid conditions that are increasingly prevalent and have a high socioeconomic burden. This article discusses their shared pathophysiology, focusing on the triad of hypertension, obesity, and aging.We
HeartRhythm
APRIL 30, 2024
Studies have suggested that early atrial fibrillation (AF) ablation is associated with improved outcomes. However, it is unknown whether these patterns hold for persistent AF among patients with heart failure with preserved ejection fraction (HFpEF).
HeartRhythm
APRIL 30, 2024
Left atrial and pulmonary artery pressure (PAP) elevation can reflect severity and dynamic status of heart failure (HF) in HF with preserved ejection fraction (pEF). Atrial fibrillation (AF) worsens HFpEF progression and pump failure, but catheter ablation can restore rhythm control in this population.
HeartRhythm
SEPTEMBER 25, 2024
The HFA–PEFF score comprising echocardiographic and laboratory data is designed to diagnose heart failure with preserved ejection fraction and holds prognostic value in patients who underwent catheter ablation for atrial fibrillation (AF).
American College of Cardiology
MARCH 21, 2024
What is the utility and validity of HFA-PEFF and H2FPEF scores for diagnosis of heart failure with preserved ejection fraction (HFpEF) in patients with symptomatic atrial fibrillation (AF)?
Circulation
JANUARY 22, 2025
Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation. Circulation, Ahead of Print.
Journal of Cardiovascular Electrophysiology
DECEMBER 17, 2024
Abstract Background Heart failure (HF) with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are associated with high morbidity and mortality.
HeartRhythm
APRIL 30, 2024
The data on comparison of parameters of diastolic dysfunction (DD) on transthoracic echocardiogram (TTE) according to the progressive stages of AF in patients with coexisting heart failure with preserved ejection fraction (HFpEF) are limited.
HeartRhythm
MAY 22, 2024
The combined effect of left ventricular ejection fraction (LVEF) and atrial fibrillation (AF) on clinical outcomes in heart failure (HF) remains complex.
HeartRhythm
APRIL 30, 2024
The combined effect of Left Ventricular Ejection Fraction (LVEF) and the presence of Atrial Fibrillation (AF) on clinical outcomes in heart failure (HF) patients remains complex.
Journal of the American Heart Association
DECEMBER 29, 2023
Journal of the American Heart Association, Ahead of Print. BackgroundHeart failure with preserved ejection fraction ≥50% is prevalent with few evidence‐based therapies. points, whereas usual care worsened by 6.9 points,P<0.001).
Journal of Cardiovascular Electrophysiology
FEBRUARY 13, 2024
Abstract Introduction Heart failure (HF) and atrial fibrillation (AF) frequently co-exist. Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF).
Circulation: Heart Failure
SEPTEMBER 27, 2023
Circulation: Heart Failure, Volume 16, Issue 11 , Page e010849, November 1, 2023. Mediation of the association between MMP-2 and HF was assessed by censoring participants who developed AF or coronary heart disease before HF. 1.81]), incident HF with preserved ejection fraction (1.44 [95% CI, 1.07–1.94]),
Circulation: Heart Failure
FEBRUARY 1, 2024
Circulation: Heart Failure, Ahead of Print. Background:NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels are variably elevated in heart failure with preserved ejection fraction (HFpEF), even in the presence of increased left ventricular filling pressures.
HeartRhythm
APRIL 30, 2024
Previous studies have demonstrated significant morbidity and mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), particularly with accompanying atrial fibrillation (AF).
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) with comorbid heart failure with preserved ejection fraction (HFpEF) presents a significant management challenge.
The British Journal of Cardiology
AUGUST 21, 2024
Digoxin has been used in the management of chronic heart failure (HF) and atrial fibrillation (AF) for over 250 years. It is the only drug that combines an inotropic effect with a reduction in ventricular rate in AF. Therefore, in theory it should be an ideal treatment for HF, especially when there is co-existent AF.
HeartRhythm
APRIL 30, 2024
A number of studies have examined the impact of atrial fibrillation (AF) ablation on outcomes in heart failure (HF) with reduced ejection (HFrEF) patients. In contrast, data from HF with preserved ejection fraction (HFpEF) patients is limited to small outcome studies and less robust meta-analyses.
HeartRhythm
APRIL 30, 2024
Overtime, various studies have reported variable mortality outcomes in heart failure with preserved ejection fraction (HFpEF) patients.
HeartRhythm
OCTOBER 18, 2024
The impact of comorbidity burden on outcomes of radiofrequency catheter ablation (RFCA) for atrial fibrillation (AF) in patients with heart failure and preserved ejection fraction (HFpEF) remains unclear.
HeartRhythm
JUNE 23, 2024
Catheter ablation has become the most effective rhythm control strategy in treating atrial fibrillation (AF), preventing AF recurrence and delaying its progression to persistent AF better than antiarrhythmic drugs.
HeartRhythm
APRIL 30, 2024
Studies have shown an overriding benefit of AF ablation in patients with long-standing HFrEF and symptomatic AF. Any benefit from active AF intervention in patients with HFpEF has been less certain.
DAIC
FEBRUARY 29, 2024
24 will focus on the following three current guideline updates: American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines 2023 Atrial Fibrillation Guideline - Pharmacology II: Strokes vs. Bleeds, What Do the Guidelines Tell Us About Practical Management in A-fib? The Guidelines Sessions at ACC.24
103 European Journal of Heart Failure
DECEMBER 20, 2023
Abstract Introduction Emerging evidence suggests a beneficial effect of higher heart rates in some patients with heart failure with preserved ejection fraction (HFpEF).
European Journal of Heart Failure
APRIL 13, 2025
The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status.
DAIC
MARCH 25, 2025
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
DAIC
MARCH 25, 2025
Ten presentations will feature new data from the pivotal Phase III FINEARTS-HF cardiovascular (CV) outcomes trial, which investigated KERENDIA for treatingt adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
Journal of Cardiovascular Electrophysiology
OCTOBER 21, 2024
Abstract Introduction Catheter ablation for atrial fibrillation (AF) reduces heart failure (HF) hospitalization in patients with HF with preserved ejection fraction (HFpEF).
European Journal of Heart Failure
DECEMBER 19, 2024
BNP, B-type natriuretic peptide; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular filtration rate; EP, endpoint; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SwedeHF, Swedish Heart Failure Registry; US, United States.
European Journal of Heart Failure
DECEMBER 7, 2023
ABSTRACT Background Left atrial (LA) myopathy is increasingly recognized as an important phenotypic trait in heart failure (HF) with preserved ejection fraction (HFpEF). 2.92, p = 0.01). Further study is required to define optimal strategies to treat and prevent biatrial myopathy in HFpEF.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content